Northeast Pharmaceutical Group Co Ltd

Hangxiao Steel Structure has signed a $166 million procurement contract for a DEP project with Dangote Petroleum Refining Free Zone Enterprise, securing a major order. Meanwhile, three government departments issued guidelines on overseas competition conduct and compliance building for the automotive industry, regulating companies' overseas pricing strategies. The world's first international standard for legged robots, led by China, has been officially released, and China has achieved a major breakthrough in the comprehensive utilization of refractory iron ore resources. China Securities Index Company will launch four artificial intelligence-related indices. Eurozone inflation rose to 3.3% in August. Other company updates include: Huanrui Century said revenue from AIGC business accounts for a low proportion; Bona Film Group's AI film and television business is still in its early stages; Seagull Housing reminded of the risk of abnormal share price increases; Jitai Corporation's liquid cooling silicone oil has not formed large-scale orders; BAIC BluePark's August sales rose 29.88% year-on-year; Huaxia Eye Hospital's actual controller plans to increase holdings by no less than 30 million yuan; Northeast Pharmaceutical's director plans to reduce holdings; KTK Group's shareholder plans to reduce holdings by no more than 3%; Zhongji Innolight repurchased 374,100 shares for the first time at a cost of 318 million yuan; Shandong University Electric Power won a bid for a China Southern Power Grid project worth about 15.806 million yuan; Far East Smarter Energy's August winning bids and signed contract orders totaled 1.78 billion yuan; Sunshine Corporation's subsidiary signed a 633 million yuan server leasing contract; and GigaDevice expects the DRAM supply shortage will not ease significantly by 2027.

Northeast Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 83.8646 million yuan, down 35.08% from the same period last year. Total operating revenue was 3.333 billion yuan, down 13.49% year-on-year. Net cash flow from operating activities was negative 73.9632 million yuan, down 170.36% year-on-year. The company's latest asset-liability ratio was 58.37%, gross margin was 32.42%, ROE was 1.52%, and diluted earnings per share was 0.06 yuan.

Northeast Pharmaceutical released its 2026 half-year report. First-half operating revenue was 3.333 billion yuan, down 13.5% year on year. Net profit attributable to the parent company was 83.86 million yuan, down 35.1% year on year. Net operating cash flow was negative 73.96 million yuan, down 170.4% year on year. Second-quarter operating revenue was 1.33 billion yuan, down 30.4% year on year, and net profit attributable to the parent company was 57.23 million yuan, down 38.4% year on year. The company said the profit decline was mainly due to the pharmaceutical distribution segment's gross margin of only 5.13%, a 40.90% drop in other income such as government subsidies, and an 872% increase in financial expenses. By segment, pharmaceutical manufacturing revenue fell 20.98% year on year, while pharmaceutical distribution revenue fell 8.7% year on year.

Northeast Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 83.86 million yuan, down 35.1% year on year. Operating revenue was 3.333 billion yuan, down 13.5% year on year. Net profit attributable to the parent after deducting non-recurring items was 57.24 million yuan, down 35.9% year on year. Net operating cash flow was negative 73.96 million yuan, down 170.4% year on year. In the second quarter, operating revenue was 1.33 billion yuan, down 30.4% year on year, and net profit attributable to the parent was 57.23 million yuan, down 38.4% year on year. As of the end of the second quarter, the company's total assets were 13.578 billion yuan, up 5.3% from the end of the previous year, and net assets attributable to the parent were 5.534 billion yuan, up 0.1% from the end of the previous year.